Axonal Integrity Biomarkers in Healthy Brain Aging

Abstract

Axonal integrity is fundamental to maintaining cognitive and neurological function throughout the human lifespan. This review examines the current landscape of axonal integrity biomarkers in the context of healthy brain aging, highlighting their pathophysiological significance, diagnostic utility, and clinical implications. We synthesize evidence from neuroimaging, cerebrospinal fluid (CSF), and blood-based biomarkers, providing clinicians and researchers with an updated perspective on mechanistic underpinnings, risk factors, and guideline-driven recommendations for monitoring brain health in the aging population.

Introduction

Brain aging is a complex interplay of structural, functional, and molecular processes that may ultimately impair cognitive resilience and neural connectivity. Axons, as the primary conduits of neuronal communication, are particularly susceptible to age-related changes, making axonal integrity a pivotal focus in the study of neurobiological aging. Biomarkers that reflect axonal health have emerged as valuable tools in tracking subclinical brain changes and informing risk stratification, early intervention, and personalized care strategies for older adults.

Epidemiology / Disease Burden

The global demographic shift toward an aging population underscores the critical need for sensitive and specific biomarkers of neurodegeneration. Although not all aging brains develop overt neurodegenerative disease, subtle axonal alterations accumulate with age and can precede clinically apparent symptoms by decades. Epidemiological studies reveal that even in cognitively healthy individuals, axonal degeneration markers correlate with age and are predictive of future cognitive decline, reinforcing the clinical value of early detection.

Pathophysiology

Axonal integrity encompasses the structural and functional preservation of axonal membranes, cytoskeleton, and myelin. Aging leads to decreased axonal transport, increased oxidative stress, mitochondrial dysfunction, and low-grade inflammation—all of which contribute to axonal damage. Key mechanistic biomarkers, including neurofilament light chain (NfL), tau protein, and myelin breakdown products, have been linked to these processes. Advanced neuroimaging metrics, such as diffusion tensor imaging (DTI), provide in vivo quantitative assessments of white matter tract integrity, elucidating microstructural changes associated with age.

Risk Factors

Multiple modifiable and non-modifiable factors influence axonal integrity in aging. Genetic predispositions (e.g., APOE ε4 allele), cardiovascular comorbidities, metabolic syndrome, chronic inflammation, sedentary lifestyle, and environmental exposures synergistically accelerate axonal degeneration. Conversely, factors such as cognitive engagement, physical activity, and optimal vascular health may confer resilience, highlighting the importance of integrative risk assessment and preventive strategies targeting axonal health.

Clinical Features

In healthy aging, axonal dysfunction often manifests subclinically, with subtle changes in cognitive processing speed, attention, and executive function. Unlike overt neurodegenerative conditions, healthy older adults may remain asymptomatic despite detectable reductions in axonal integrity biomarkers. Longitudinal studies indicate that even mild elevations in NfL or white matter hyperintensity burden on MRI can portend higher risk for future cognitive impairment, emphasizing the prognostic relevance of these biomarkers in routine geriatric assessment.

Diagnosis

Diagnosis of axonal compromise in aging relies on a combination of fluid-based biomarkers and advanced neuroimaging. Plasma and CSF NfL levels are sensitive indicators of axonal injury, with growing evidence supporting their use in distinguishing healthy aging from early neurodegenerative disease. MRI-based techniques, such as DTI and tract-based spatial statistics, provide complementary information on white matter microarchitecture. Integration of biomarker data with neuropsychological testing enables comprehensive phenotyping of brain aging trajectories.

Treatment & Management

While no specific therapies currently exist to restore axonal integrity in the context of healthy aging, several intervention strategies are under investigation. Optimizing cardiovascular risk factors, promoting regular physical exercise, and adopting anti-inflammatory dietary patterns have been associated with reduced axonal degeneration rates. Pharmacological approaches, including neuroprotective agents and remyelination therapies, are active areas of research. Clinical management focuses on modifiable risk factor control and regular monitoring of cognitive and biomarker status in at-risk individuals.

Recent Advances / Emerging Therapies

Recent years have seen significant advancements in the sensitivity and accessibility of axonal integrity biomarkers. Ultra-sensitive single-molecule array (Simoa) assays have enabled reliable quantification of plasma NfL, facilitating large-scale population studies. Machine learning models integrating multi-modal biomarker data show promise in predicting brain aging patterns and identifying individuals at risk for accelerated decline. Novel therapeutic targets under investigation include agents that enhance axonal transport, mitigate oxidative damage, and promote remyelination. Ongoing clinical trials are evaluating the impact of lifestyle interventions and pharmacological modulators on axonal biomarkers and cognitive outcomes.

Guideline Recommendations

Current consensus guidelines from leading neurology and geriatrics societies emphasize the integration of axonal integrity biomarkers into research protocols and, where validated, into clinical assessment frameworks for aging populations. Routine use of plasma NfL and MRI-based white matter integrity measures is recommended for risk stratification and monitoring in research settings, with clinical translation expected as normative reference ranges and predictive thresholds are refined. Multidisciplinary, personalized approaches to brain health monitoring are encouraged, prioritizing early identification and intervention for individuals with biomarker evidence of accelerated axonal aging.

Conclusion

Axonal integrity biomarkers represent a transformative advance in the understanding and management of healthy brain aging. Their ability to detect subclinical neurobiological changes, predict cognitive outcomes, and inform preventive strategies positions them at the forefront of geriatric neuroscience. Continued research into the mechanistic drivers of axonal degeneration and the development of targeted interventions will be essential to preserving cognitive vitality across the lifespan.